Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Blisibimod in Systemic Lupus Erythematosus (KCT0000967)
KCT0000967Phase 3Recruiting
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Nov 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Blisibimod arm with Placebo arm (2 arms). Started Nov 2013; status: recruiting.
02
Drugs
blisibimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on KCT0000967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000967.